title: Design and characterization of chitosan-alginate microspheres for ocular delivery of azelastine.
abstract: The use of mucoadhesive biopolymers is one of the best approaches to prolong the drug residence inside the cul-de-sac, consequently increasing the bioavailability. Thus, the focus of this work was to develop mucoadhesive microspheres to overcome the limitations of ocular drug delivery. The chitosan-sodium alginate microspheres of azelastine hydrochloride were fabricated using modified ionotropic gelation technique. The particle size, zeta potential, entrapment efficiency and drug release kinetics were evaluated and characterized by SEM, FT-IR, DSC, in vitro mucoadhesion and in vivo study. The microspheres had average particle size in the range of 3.55 to 6.70 µm and zeta potential +24.55 to +49.56 mV. The fabricated microspheres possess maximum drug entrapment of 73.05% with 65% mucin binding efficiency and revealed a controlled release over the 8-h period following a non-Fickian diffusion. SEM showed that microspheres were distinct solid with irregular shape. FT-IR and DSC results concluded the drug entrapment into microspheres. In vivo studies on ocular rat model revealed that azelastine microspheres had better efficacy. Chitosan sodium alginate microspheres prepared were in particle size range suitable for ocular purpose. In vitro release and in vivo efficacy studies revealed that the microspheres were effective in prolonging the drug's presence in cul de sac with improved therapeutic efficacy.
authors.affiliation: Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Mumbai , Maharashtra , India.
authors.forename: Ujwala A
authors.initials: UA
authors.lastname: Shinde
authors.forename: Jaykumar N
authors.initials: JN
authors.lastname: Shete
authors.forename: Hema A
authors.initials: HA
authors.lastname: Nair
authors.forename: Kavita H
authors.initials: KH
authors.lastname: Singh
mesh_terms: D000464:Alginates / Q000737:chemistry*; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D048271:Chitosan / Q000737:chemistry*; D003231:Conjunctivitis / Q000188:drug therapy* / Q000473:pathology; D003692:Delayed-Action Preparations / Q000737:chemistry*; D005123:Eye / Q000187:drug effects / Q000473:pathology; D005260:Female; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D008863:Microspheres; D010793:Phthalazines / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000464:Alginates; D018926:Anti-Allergic Agents; D003692:Delayed-Action Preparations; D006603:Hexuronic Acids; D010793:Phthalazines; D020723:Glucuronic Acid; D048271:Chitosan; C020976:azelastine